An Open-label, Dose Escalation + Dose Expansion Phase 1 Trial to Determine the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 Given Orally to Patients With Chronic Myeloid Leukemia Who Are Resistant or Intolerant to TKI Treatments | Arctuva